Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort of pediatric patients with pulmonary arterial hypertension (PAH) in Japan. The study, “Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial…
News
Complexa has obtained $62 million in financing to continue advancing its pulmonary arterial hypertension therapy CXA-10 through the clinical trial process. The company is also developing CXA-10 as a treatment for kidney disease focal segmental glomerulosclerosis, or FSGS. Companies that participated in Complexa’s third round of financing included New Enterprise…
The survival rate of pulmonary hypertension patients who received heart and lung transplants increased after France began giving transplant priority to those experiencing life-threatening episodes, a study reports. The high-priority list covered PH patients who had signed up for heart-lung transplants, or HLTs, and double lung transplants, or  DLTs. Researchers published…
Long-term Prostacyclin Use Increases Risk of a Heart Problem After a Lung Transplant, Study Reports
Pulmonary hypertension patients who receive prostacyclin for a long time are at higher risk of developing cardiovascular complications after a lung transplant, a Japanese study reports. The research, published in the International Heart Journal, was titled “High Frequency of Acute Adverse Cardiovascular Events After Lung Transplantation in Patients…
Two Pulmonary Hypertension Groups Sign Up for ZappRx’s Streamlined Prescription-ordering Service
Two pulmonary hypertension treatment groups are now working with a company that helps doctors to streamline the complex process of obtaining insurance company sign-offs on speciality prescriptions, which can take weeks. Arizona Pulmonary Specialists in Phoenix and the pulmonary hypertension unit at Harbor-UCLA Medical Center in Torrance, California, have become clients of  ZappRx. The process…
Obese people with pulmonary arterial hypertension (PAH) are less likely than patients of normal weight to die while hospitalized, finds a study examining the so-called “obesity paradox.” The study, “Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to…
The exercise capacity of people with scleroderma who have yet to develop pulmonary arterial hypertension (PAH) diminishes over time, according to an Austrian study. Their lung function during exercise also deteriorates little by little, researchers at the Medical University of Graz reported. The findings raise the question of whether PAH treatment…
Mount Sinai, Theragene Form Partnership to Move Potential PH Gene Therapy to Clinical Development
New York’s Mount Sinai and Theragene Pharmaceuticals have joined efforts to move a novel investigational aerosol-delivered gene therapy to treat pulmonary hypertension (PH) into a clinical development program. The new therapy, if approved, will be the first to reverse the tissue damage caused by PH. Clinical trials should begin in…
Arena Pharmaceuticals has announced positive results for ralinepag (APD811), an investigational prostacyclin receptor agonist being investigated in a Phase 2 trial to treat pulmonary arterial hypertension (PAH). Ralinepag is an oral drug that targets the prostacyclin pathway. The drug was developed for the treatment of PAH, due to its action on…
Aironite Mist Lowers Blood Pressure in Hearts of Pulmonary Hypertension Patients, Trial Update Shows
Savara’s inhaled sodium nitrite therapy Aironite lowered blood pressure in the upper and lower heart chambers and pulmonary artery of pulmonary hypertension patients, according to an update of a Phase 2 clinical trial. The most improvement occurred in PH patients with a condition known as heart failure with preserved ejection…
Results of a Phase 1 clinical study in healthy volunteers evaluating different formulations of Arena Pharmaceuticals’ prostacyclin receptor agonist, ralinepag, for the treatment of pulmonary arterial hypertension (PAH), showed the drug’s extended release (XR) formulation can achieve a similar body distribution profile as its immediate release (IR) capsule formulations, but with…
Elevated levels of a protein called adipsin, produced by adipose or fat tissue, was found to be associated with an increased risk of pulmonary arterial hypertension (PAH) and associated cardiovascular deregulation in patients with systemic sclerosis (SSc). The findings were reported in a report titled “Elevated Adipsin Levels are…
Recent Posts
- PALBI blood score may identify high-risk pulmonary hypertension patients
- When living with PH, there’s no such thing as a minor case of the flu
- New CHEST program offers pulmonary certification for providers
- Legal settlement secures long-term access to Yutrepia for PAH patients
- Finding emotional support while living with pulmonary hypertension
